Diclosian

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diclosian

Quick Facts about Diclosian (Diclofenac)

Property Description
Active Ingredient Diclofenac (often as the sodium or potassium salt)
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common Use Symptomatic relief of pain, inflammation, and fever
Origin Synthetic compound (Phenylacetic acid derivative)
High-Level Forms Oral preparations (tablets), Topical preparations (gels), Injectable solutions

What is Diclosian?

Diclosian is a pharmaceutical product defined by its active chemical component, Diclofenac, and classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This medication is a synthetic compound derived from phenylacetic acid, specifically engineered to provide relief from symptoms associated with inflammation and pain.


What Type of Medicine is Diclosian (Diclofenac)?

Diclosian belongs to the Nonsteroidal Anti-inflammatory Drug (NSAID) class of medication, which makes it an anti-inflammatory agent with recognized analgesic and antipyretic properties. Diclofenac is recognized globally as an important drug for managing pain and inflammation, a role established for decades across various pain management guidelines. The drug's identity as a synthetic compound enables it to deliver a predictable and targeted effect against inflammation.


Diclosian's Active Composition and Available Forms

The efficacy of Diclosian stems from its main active ingredient, Diclofenac, which is typically presented as the sodium or potassium salt. Diclofenac is generally a single-active-ingredient product. The medication is made available in diverse high-level dosage forms. These forms include oral preparations (such as tablets or capsules), topical preparations (like gels or solutions), and occasionally, injectable solutions. This variety means the preparation is suited for different routes of administration, allowing the Diclofenac to exert its effect locally or systemically, depending on the form.


What is the General Purpose of Diclosian?

The general purpose of Diclosian is to alleviate the symptoms of inflammation, pain, and fever. For example, it is typically used in the management of painful swelling and discomfort following a sprain or soft tissue injury. By providing both anti-inflammatory and analgesic relief, the medication helps to manage discomfort and swelling caused by various conditions. This comprehensive action is central to the role of all NSAIDs, offering a dual benefit that addresses both the symptomatic discomfort and the underlying inflammatory process itself.

Regulatory References

  1. World Health Organization
  2. WHO Model Lists of Essential Medicines
  3. U.S. National Library of Medicine
  4. Diclofenac: MedlinePlus Drug Information

What side effects are possible with Diclosian?

Diclosian: Possible Side Effects and Safety Information

Serious and Clinically Significant Adverse Reactions

The most serious safety concerns associated with Diclosian, based on regulatory warnings, involve potentially fatal cardiovascular (CV) thrombotic events (including myocardial infarction and stroke) and severe gastrointestinal (GI) adverse events (including bleeding, ulceration, and perforation of the stomach or intestines). The risk of these events may increase with higher doses and longer duration of use. Additionally, serious skin reactions (such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS]) and severe anaphylactic reactions have been documented.

System Organ Class
Cardiovascular/Vascular Thrombotic events, hypertension, fluid retention, and edema.
Gastrointestinal Abdominal pain, nausea, vomiting, diarrhea, constipation, dyspepsia, and flatulence are common.
Hepatobiliary Liver test elevations; severe hepatic reactions are rare but possible.
Renal/Urinary Renal toxicity, including papillary necrosis, especially with long-term use.

Population-Specific Safety Considerations and Restrictions

Diclosian is contraindicated in patients undergoing coronary artery bypass graft (CABG) surgery, those with a history of asthma or allergic-type reactions after taking aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), and those with established severe heart failure or ischemic heart disease. Elderly patients and those with pre-existing cardiovascular risk factors, GI disease, or impaired renal/hepatic function are at greater risk for serious adverse events and require cautious use. The drug must be avoided starting at about 30 weeks gestation due to the risk of fetal toxicity (e.g., premature closure of the fetal ductus arteriosus).

To minimize risk, official documentation recommends using the lowest effective dose for the shortest duration consistent with individual treatment goals. Close monitoring of blood pressure, renal function, and liver tests is noted as a high-level safety measure during therapy.

Overdose and Emergency Response

Diclosian Overdose and when to seek help

The official regulatory profile for Diclosian overdose focuses on documented clinical presentations and the immediate need for emergency intervention, strictly as described in government labeling.

Category Official Regulatory Statements
Documented Manifestations Acute presentations include epigastric pain, nausea, vomiting (sometimes with blood), lethargy, drowsiness, dizziness, and headache.
Severe Systemic Outcomes Documented risks involve Gastrointestinal (bleeding, perforation), Renal (acute failure, oliguria), Central Nervous System (seizures, coma, respiratory depression), and Cardiovascular (hypotension, tachycardia).
Population-Specific Notes Overdose-related gastrointestinal events have more serious consequences in the elderly. Severe kidney damage may require dialysis.

Seeking Urgent Medical Attention

Individuals must seek immediate medical attention or contact a Poison Control Center right away if an overdose is suspected or if severe systemic adverse effects, such as seizures or anaphylaxis, occur.

Official Management Statements:

  • Management focuses on supportive care and general therapeutic measures for NSAID poisoning.
  • The potential use of activated charcoal or gastric decontamination may be considered.
  • There is no specific antidote known to manage Diclosian overdose.

The documented clinical profile establishes a risk progression from common initial symptoms to severe toxicity. This necessitates prompt medical evaluation and treatment guided by supportive measures, as regulatory information explicitly confirms the absence of a specific antidote.

Therapeutic Uses of Diclosian

What Diclosian treats: Main Uses and Benefits

Diclosian is commonly used to help with symptoms related to inflammatory or irritative states across key therapeutic domains. The medication is generally applied in contexts where additional symptomatic support is needed to address discomfort.

It is relevant in conditions characterized by periods of heightened symptoms such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It is also commonly used to manage acute pain episodes like migraine attacks, gout flares, and severe primary dysmenorrhea, and provides support for injury and post-procedural recovery, including post-traumatic pain from sprains or postoperative pain following surgery. It is applied in addressing symptom clusters that may become intense or disruptive.

“The medication assists with easing discomfort and supports general well-being during symptomatic periods.”

The overall therapeutic benefit contributes to easing the overall symptom load and supports general well-being during symptomatic periods.


Relief for Pain, Inflammation, and Fever
Diclosian is commonly used across domains involving heightened systemic burden to manage groups of symptoms including musculoskeletal pain, swelling, and associated fever.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Diclosian (Diclofenac)

Official regulatory documents define specific population eligibility rules for Diclosian based on absolute prohibitions and conditional use requirements. The medicine is contraindicated and must not be used in several groups.


Absolute Non-Eligibility

Population Group Restriction Basis
Cardiovascular Risk Patients with established Congestive Heart Failure (NYHA Class II–IV), Ischaemic Heart Disease, Peripheral Arterial Disease, or Cerebrovascular Disease [EMA SmPC].
Gastrointestinal Integrity Patients with active or recurring peptic ulceration, bleeding, or perforation; or history of GI bleeding related to NSAIDs [FDA Label].
Allergy & Sensitivity Known hypersensitivity to Diclofenac, aspirin, or any other NSAID, including those with NSAID-induced asthma or urticaria.
Pregnancy Stage Use is contraindicated during the third trimester of pregnancy due to fetal risk.
Surgical Setting For the treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Organ Failure Patients with severe hepatic failure or severe renal failure.

Conditional and Restricted Use

Use requires caution and medical surveillance in older adults, due to increased risk of serious adverse events, and in patients with mild-to-moderate renal or hepatic impairment. Pediatric use is restricted and often not established for general indications, varying by formulation and regulatory region.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Diclosian (Diclofenac) identifies several categories of interactions documented in government sources, primarily categorized by pharmacodynamic and pharmacokinetic outcomes.


Additive Pharmacodynamic and Gastrointestinal Risks

Concomitant use with other oral Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including analgesic doses of Aspirin, is not generally recommended due to an increased risk of serious gastrointestinal (GI) adverse events. Diclosian may interfere with hemostasis, and co-administration with Anticoagulants (e.g., Warfarin) or other agents that affect clotting, such as Antiplatelets or certain Antidepressants (SSRIs/SNRIs), carries a heightened risk of serious GI bleeding. The use of alcohol is also officially documented to increase this risk.

Drug Exposure Modification and Efficacy

Diclosian may alter the plasma concentrations of certain co-administered medicines. The use of CYP2C9 inhibitors (e.g., Voriconazole) is documented to increase systemic exposure to Diclosian itself. Conversely, Diclosian can result in increased serum concentrations of drugs like Lithium, Methotrexate, and Digoxin, due to reduced clearance. Diclosian may also diminish the therapeutic effectiveness of antihypertensive agents, including ACE-inhibitors and ARBs, and can reduce the natriuretic effect of Diuretics.

Timing and Population Restrictions

Specific administrative constraints are documented for Diclosian. The oral solution formulation must be consumed on an empty stomach to avoid reduced effectiveness. Additionally, caution regarding deteriorating renal function is noted for the co-administration of Diclosian with ACE-inhibitors/ARBs in the elderly, volume-depleted, or renally impaired populations. Diclosian use must also be avoided for two days before, the day of, and two days following administration of Pemetrexed in patients with specific renal impairment.

Mechanism of Action

Diclosian is a small molecule that acts as a non-competitive inhibitor of the farnesyl pyrophosphate synthase (FPPS) enzyme. This enzyme is an essential component of the mevalonate pathway.

By binding to a site separate from the active center, Diclosian restricts the synthesis of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), which are necessary lipid substrates for the post-translational modification known as prenylation. The resulting depletion of FPP and GGPP prevents the prenylation of small GTPase signaling proteins, such as Ras and Rho.

This disruption prevents the requisite membrane localization and subsequent activation of these GTPases. The failure of these signaling proteins to anchor to the membrane and activate leads to a downstream cascade that modulates cell adhesion, alters cytoskeletal dynamics, and shifts intracellular proliferative signaling cues. This results in a system-level physiological consequence characterized by modified cellular scaffolding integrity and motility.

Dosage and Administration Information

Diclosian is administered through multiple official routes, including oral (as tablets, capsules, or solution packets), topical (gels and solutions), and parenteral (intramuscular or intravenous injection) forms. The standard principle across all forms is to use the lowest effective dosage for the shortest duration necessary to meet usage needs.

Systemic dosing typically ranges from 100 mg to 200 mg per day, and this total daily amount is often divided into two to four separate administrations. For chronic systemic use, the frequency is commonly twice or three times daily, depending on the specific formulation and indication. The total daily intake must not exceed the specific maximum dose established for the relevant route and form.

Procedural compliance is essential for proper administration. For instance, oral delayed-release tablets must be swallowed whole and must not be crushed, chewed, or split to maintain the drug’s intended release profile. Certain oral powder formulations require mixing with a small amount of water and are typically instructed to be taken without food. Intravenous solutions require dilution and buffering prior to infusion, and this route is generally limited to a maximum of two days.

Regarding specific populations, the general approach is to use the lowest effective dosage for older adults. If a dose is missed, the instruction is to skip the missed dose and resume the next scheduled administration, rather than doubling the dose.

Recent Clinical Evidence

Diclosian: Research Evidence Overview


Evidence for Use in Chronic and Acute Conditions

The research base for Diclosian involves Randomized Controlled Trials (RCTs) and Meta-analyses that explored its use in conditions with episodic or heightened symptoms. Studies were primarily evaluated in research exploring chronic inflammatory arthritis (such as osteoarthritis and rheumatoid arthritis) and acute pain episodes. Investigators focused on patient-reported outcomes describing perceived discomfort, specifically measuring changes in pain intensity and physical function scales over short and intermediate time periods.

Topical formulations were studied in Double-Blind, Randomized Trials for localized musculoskeletal pain, primarily in accessible joints like the knee and hand. These studies monitored local pain and functional status, and investigators monitored patterns of systemic absorption for comparison against oral formulations. For acute, time-limited pain (e.g., postoperative pain), trials focused on very short-term outcomes measured over 24 to 48 hours, monitoring changes in pain intensity versus placebo.


Long-Term Data and Specific Patient Populations

Data for extended duration use (beyond one year) primarily comes from open-label extension studies and large-scale observational settings. This research provides context regarding administration patterns but does not provide the same level of structured evidence as controlled efficacy trials. Research has explored its use in specific adult populations, including older adults and groups with comorbid conditions, as well as adolescent patients for acute pain; however, data for certain groups remain insufficient.


Gaps in Research and Areas of Uncertainty

Follow-up durations were limited in many core trials, meaning research provides context but not individual predictions about symptom patterns over many years. Evidence quality varies across studies, and comparative evidence is lacking for some of the newer topical forms against other specific local treatments. Subgroup findings are uncertain when trying to generalize research to populations with complex or multiple pre-existing health conditions. The evidence describes what has been observed in the specific conditions under which the studies were conducted, and research is ongoing.

Key Studies & References

  1. Diclofenac (oral route) - MedlinePlus Drug Information (Used for regulatory/indication context)

Frequently Asked Questions (FAQ)

Common questions about Diclosian (FAQ)


Q: What are the main conditions Diclosian is officially approved to treat?

Diclosian is officially approved to manage the signs and symptoms of several chronic inflammatory conditions, including rheumatoid arthritis and osteoarthritis. The official documents also indicate its use for certain acute pain and inflammation conditions, such as ankylosing spondylitis and primary dysmenorrhea.

Q: Are there any long-term safety concerns associated with using Diclosian?

Regulatory documents indicate that the risk of serious adverse events may increase with longer durations of use. These safety concerns include the potential for cardiovascular thrombotic events and severe gastrointestinal issues. Long-term use is also associated with a greater potential for renal (kidney) toxicity, and monitoring is often noted in regulatory materials as a high-level safety measure.

Q: What are the severe, but rare, side effects of Diclosian?

Severe, rare documented effects are detailed in official product information. These adverse reactions include serious liver problems, severe blistering skin reactions such as Stevens-Johnson syndrome, and acute kidney damage.

Q: How often do people experience nausea when taking Diclosian?

Nausea is classified in official regulatory documents as a common side effect. This classification means that, based on clinical trial data, it may affect between 1 in 100 and 1 in 10 patients who use Diclosian.

Q: What types of over-the-counter medicines should not be taken with Diclosian?

Official documents state that co-administration with other nonsteroidal anti-inflammatory drugs (NSAIDs) or aspirin is not recommended. This restriction is due to an increased risk of serious gastrointestinal adverse events, such as bleeding and ulceration.

Q: Should Diclosian be taken with a meal or on an empty stomach?

The instruction for taking Diclosian depends on the specific formulation being used. For example, oral powder solutions may require an empty stomach, while delayed-release tablets are generally taken with food or milk. This approach is often noted in product information to help minimize the possibility of stomach upset.

Q: What is the official guidance regarding Diclosian use during pregnancy or breastfeeding?

Official guidance states that use is strictly contraindicated during the third trimester of pregnancy due to documented risks to the fetus. Diclosian is reported to pass into breast milk in small amounts, and official documents note the need for caution or avoidance during this period.

Q: Is Diclosian a new drug or has it been used for a long time?

Diclosian (Diclofenac) is a well-established medication that has been used clinically for several decades. It is widely recognized across the globe and is included on the World Health Organization's Model List of Essential Medicines.

Q: Is Diclosian ever used to treat migraine headaches?

Yes, official indications show that certain specific formulations of Diclosian are approved for the acute treatment of migraine headaches with or without aura. This typically includes formulations designed for rapid absorption, such as the oral powder solution.

Q: What should be known about Diclosian and stomach protection?

Official documents acknowledge the high risk of serious gastrointestinal issues associated with this medication. Official documents describe that for certain high-risk patients with a history of stomach problems, the use of gastroprotective agents (such as proton pump inhibitors) is noted as a safety measure to mitigate risk.

Q: Is Diclosian a prescription-only medication?

Diclosian’s classification varies by strength and preparation. Some higher-strength formulations are available only as a prescription-only medicine (POM). However, other lower-strength forms, especially topical gels, are often classified as over-the-counter (OTC) products, depending on the specific regulatory region.

Q: Is Diclosian known to cause drowsiness or dizziness?

Official product information documents dizziness, drowsiness, and somnolence (sleepiness) as potential side effects of Diclosian. Official information indicates that these effects are possible during use.

Q: Can Diclosian be taken with antacid medicines?

Antacids may generally be taken with certain Diclosian formulations to help reduce stomach upset. However, official information notes that some antacids, particularly those containing magnesium, may slow the absorption of the drug, potentially delaying the onset of pain relief.

Q: How quickly does Diclosian typically start to provide pain relief?

For immediate-release oral formulations, Diclosian typically reaches its maximum concentration in the bloodstream within one to two hours. This timing generally corresponds to the timeframe when the onset of pain relief is expected.

Q: How long does the effect of Diclosian usually last?

The duration of effect for immediate-release forms of Diclosian generally lasts between four and eight hours. This length of effect aligns with the drug's short half-life and the common administration frequency.

Q: Is Diclosian known to cause weight gain or loss?

While weight changes are not usually listed as a primary side effect, official documents do list fluid retention and edema (swelling) as documented adverse reactions. These effects can contribute to changes in body weight.

Q: Can Diclosian cause a sensitivity to sunlight?

Increased sensitivity to sunlight, known as photosensitivity, is a documented but uncommon side effect of Diclosian. Official patient information notes that sun exposure should be limited during the use of this medication.

Q: Does Diclosian affect fertility?

Official regulatory documentation includes a note that, similar to other medicines that inhibit prostaglandin synthesis, Diclosian may temporarily impair female fertility. This effect is reported as reversible upon withdrawal of the drug.

How should Diclosian be stored and disposed of?

The storage and disposal of Diclosian (diclofenac) must follow official regulatory requirements. The medicine must be stored at controlled room temperature, typically 20 C to 25 C, and should be protected from moisture and excessive heat. It is explicitly required to keep the medicine in its original container and do not refrigerate or freeze specific formulations. All Diclosian must be kept out of the sight and reach of children. For certain topical gels, the in-use period is limited, and the product must be discarded 6 months after first opening. Disposal should be via an authorized drug take-back program. If unavailable, the medicine must be mixed with an unappealing substance, sealed in a container, and discarded in the household trash to prevent misuse.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diclosian found in:

A-Z Index: